Ancillary Review Boards
An institutional review board (IRB) is one type of review board that investigators may work with while conducting research at NYU Grossman School of Medicine. Depending on the nature of your clinical trial or research study, you may also need to submit your protocol to other groups for review to ensure that it meets the necessary regulations.
Learn more about the following committees, institutes, and offices that review research at NYU Langone:
- Protocol Review and Monitoring Committee
- Research Conflicts of Interest Committee
- Radiation Safety Office
- Institutional Biosafety Committee
- Clinical and Translational Science Institute
- Embryonic Stem Cell Research Oversight Committee
- Bellevue Research Review Committee
All cancer-related protocols must be reviewed by the Protocol Review and Monitoring Committee, also known as the PRMC. The Clinical Research Support Unit provides administrative support for the PRMC. For further information, email firstname.lastname@example.org.
All conflicts of interest in research are reviewed by the Conflicts of Interest Management Unit. Conflicts of interest considered significant are reviewed by the Research Conflicts of Interest Committee. For more information, please log into the webpage of the Conflicts of Interest Management Unit using your Kerberos ID or contact the unit at 212-404-4079.
Two policies cover conflicts of interest:
- Policy on Conflicts of Interest in Research and Sponsored Programs replaces the Investigator Financial Interest Disclosure and Conflict of Interest Policy dated October 1, 1995. This policy applies to all investigators participating in sponsored research conducted at or under the auspices of NYU Grossman School of Medicine and NYU Langone.
- Policy on Institutional Conflicts of Interest in Human Subjects Research applies to financial interests that NYU Grossman School of Medicine or NYU Langone may have in human subjects research being conducted at the institution.
The Radiation Safety Office is based at NYU Grossman School of Medicine but serves as an institutional resource for all of NYU and for NYU Langone, NYC Health + Hospitals/Bellevue, and the VA NY Harbor Healthcare System.
The department seeks to assist researchers in achieving their educational, research, and clinical goals while ensuring safety and compliance with the many regulations associated with the use of radioactive materials and machine sources of ionizing radiation.
The department negotiates and holds various licenses and registrations that authorize the use of radiation sources at the locations under its jurisdiction and acts as an interface with associated agencies. It implements a radiation safety program, under the oversight of local radiation safety committees within the various locations, and provides support services.
The Radiation Safety Office is located at NYU Grossman School of Medicine in Medical Science Building G58 (opposite the student cafeteria). Its hours are 9:00AM to 5:00PM, Monday through Friday. If you would like to reach director Steven R. Wagner, MS, DABR, call the office at 212-263-6888.
You can also send mail to the office at the following address:
NYU Langone’s Radiation Safety Office
Medical Science Building G58
550 First Avenue
New York, NY 10016
All research that involves recombinant DNA (rDNA) molecules must be in compliance with the National Institutes of Health (NIH) guidelines for research involving rDNA molecules. NIH guidelines for safe and ethical conduct of rDNA research apply to both basic and clinical research studies.
NYU Grossman School of Medicine’s Institutional Biosafety Committee is responsible for approving risk assessment and the biosafety containment levels for such experiments.
The Clinical and Translational Science Institute is a partnership between NYU Langone and the New York City Health and Hospitals Corporation that has been designed to overcome roadblocks to clinical and translational research and to transform the way that research is carried out. The institute enhances the quality and productivity of research efforts at these institutions and across the nation as part of the NIH Clinical and Translational Science Awards consortium.
All research involving the use of human embryonic stem cells or human pluripotent stem cells must comply with NIH, National Academy of Sciences, Empire State Stem Cell Board, International Society for Stem Cell Research, and institutional regulations.
NYU Grossman School of Medicine’s Embryonic Stem Cell Research Oversight Committee reviews all research studies involving the use of human embryonic stem cells or human pluripotent stem cells and registers approved research protocols.
Before applying to conduct research at NYC Health + Hospitals/Bellevue, investigators should review the Bellevue guidance document to determine whether to list Bellevue as a site in Research Navigator.
If you determine that Bellevue is a research site, complete the following steps:
- To confirm that you have chosen Bellevue as a research site, please email email@example.com.
- Submit your study using the System to Track and Approve Research (STAR). All investigators conducting research at Bellevue must obtain approval from the Bellevue Research Review Committee and the Health + Hospitals Central Office Research Administration via STAR.
- Wait until you receive your approvals. Your study may begin at Bellevue upon the receipt of Health + Hospitals Central Office approval letter which is sent to you via the STAR system. Please note that annual renewals are required.
If you have questions regarding the STAR process or applying at Bellevue, please email firstname.lastname@example.org.
If you have NYU Langone–related questions regarding conducting research at Bellevue, please contact Bien Lee, MPA CCRC, senior research project manager in the Office of Science and Research, at 646-754-7201 or email@example.com.